172 related articles for article (PubMed ID: 8910759)
1. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
3. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers.
Buchwalder PA; Buclin T; Trinchard I; Munafo A; Biollaz J
J Interferon Cytokine Res; 2000 Oct; 20(10):857-66. PubMed ID: 11054273
[TBL] [Abstract][Full Text] [Related]
5. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G
J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
[TBL] [Abstract][Full Text] [Related]
7. Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity.
Sturgill MG; Rashidbaigi A; Liao MJ; Zhao XX; Hua J; Trout R; Knill JR; Grasing KW
J Clin Pharmacol; 2000 Jun; 40(6):606-15. PubMed ID: 10868311
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
Byhardt RW; Vaickus L; Witt PL; Chang AY; McAuliffe T; Wilson JF; Lawton CA; Breitmeyer J; Alger ME; Borden EC
J Interferon Cytokine Res; 1996 Nov; 16(11):891-902. PubMed ID: 8938564
[TBL] [Abstract][Full Text] [Related]
9. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
10. Determination of 2'-5'-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma.
Bruchelt G; Fierlbeck G; Schiebel U; Bogenschütz O; Rassner G; Niethammer D
Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):521-8. PubMed ID: 1457613
[TBL] [Abstract][Full Text] [Related]
11. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta.
Liberati AM; Horisberger MA; Palmisano L; Astolfi S; Nastari A; Mechati S; Villa A; Mancini S; Arzano S; Grignani F
J Interferon Res; 1992 Oct; 12(5):329-36. PubMed ID: 1431312
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'-oligoadenylate synthetase activity in murine liver.
Yamagata Y; Yuasa Y; Yamamoto K; Okamoto K; Igari Y; Iga K; Ogawa Y
J Interferon Cytokine Res; 2000 Feb; 20(2):153-60. PubMed ID: 10714550
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
14. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
[TBL] [Abstract][Full Text] [Related]
16. Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men.
Barouki FM; Witter FR; Griffin DE; Nadler PI; Woods A; Wood DL; Lietman PS
J Interferon Res; 1987 Feb; 7(1):29-39. PubMed ID: 3035034
[TBL] [Abstract][Full Text] [Related]
17. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
[TBL] [Abstract][Full Text] [Related]
18. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.
Witter F; Barouki F; Griffin D; Nadler P; Woods A; Wood D; Lietman P
Clin Pharmacol Ther; 1987 Nov; 42(5):567-75. PubMed ID: 2445516
[TBL] [Abstract][Full Text] [Related]
19. Interferon and 2',5'-oligo(A) synthetase activities in serum and blood mononuclear leukocytes of cattle after injection of bovine interferon-alpha 1.
Perino LJ; Short EC; Burge LJ; Winter DA; Fulton RW
Am J Vet Res; 1990 Jun; 51(6):886-92. PubMed ID: 1695068
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trials of recombinant gamma-interferon. Circulating interferon and the 2,5-oligoadenylate synthetase activity after intramuscular and inhalation administrations].
Sokolova TM; Lopatina OA; Nosik NN; Cheshik SG
Biull Eksp Biol Med; 1993 Jun; 115(6):633-4. PubMed ID: 7690616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
